We have originally shown that spontaneous granulocyte/macrophage colony (CFU-GM) formation in semisolid medium is a characteristic in vitro feature of chronic myelomonocytic leukemia (CMML). However, the clinical significance of spontaneous CFU-GM growth in CMML is unknown so far. CFU-GM growth characteristics were studied in semisolid cultures in the absence of exogenous cytokines using peripheral blood mononuclear cells in 30 patients with CMML at first presentation. The median number of CFU-GM/105 MNC of all patients was 48.5 (range 0–622) with 18 patients having colony numbers below 100 (low CFU-GM growth) and 12 patients above 100 (high CFU-GM growth). Kaplan-Meier analysis revealed that patients with high CFU-GM growth had a significantly shorter survival than patients with low CFU-GM growth (median 6.5 vs. 44.5 months, p<0.00002). The probability of survival after 2 years was 60.5% for patients with low colony growth but 0% in those with high colony formation. Patients with CFU-GM >100 had a significantly higher WBC count, a higher LDH, and a higher number of blast cells in blood and bone marrow than patients with low colony growth. Moreover, patients with high colony growth had more often splenomegaly and lower platelet counts. In seven patients, in whom semisolid in vitro cultures were performed after transformation into RAEBT/AML, spontaneous colony growth was significantly increased as compared to CFU-GM growth in patients before transformation (median number/105 MNC 533, range 212–4553, p<0.005). This study demonstrates that high (>100) spontaneous CFU-GM formation in CMML at presentation correlates with increased disease activity and represents a novel and important prognostic factor predicting for short survival of CMML patients.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. The French-American-British (FAB) Co-operative Group. Br J Haematol 51:189–199
Cox DR (1972) Regression models and life-tables. J R Stat Soc B 34:187–220
De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE (1991) Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174:1209–1220
Everson MP, Brown CB, Lilly MB (1989) Interleukin-6 and granulocyte-macrophage colony-stimulating factor are candidate growth factors for chronic myelomonocytic leukemia cells. Blood 74:1472–1476
Fenaux P, Beuscart R, Lai JL, Jouet JP, Bauters F (1988) Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol 6:1417–1424
Geary CG, Catovsky D, Wiltshow E, Milner GR, Scholes MC, Van Noorden S, Wadworth LD, Muldal S, MacIver JE, Galton DAG (1975) Chronic myelomonocytic leukemia. Br J Haematol 30:289–302
Geissler K, Hinterberger W, Bettelheim P, Haas O, Lechner K (1988) Colony growth characteristics in chronic myelomonocytic leukemia. Leuk Res 12:373–377
Geissler K, Öhler L, Födinger M, Virgolini I, Leimer M, Kabrna E, Kollars M, Skoupy S, Bohle B, Rogy M, Lechner K (1996) Interleukin 10 inhibits growth and granulocyte/macrophage colony-stimulating factor production in chronic myelomonocytic leukemia cells. J Exp Med 184:1377–1384
Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. JCO 17:3835–3849
Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457
Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170
Oehler L, Foedinger M, Koeller M, Kollars M, Reiter E, Bohle B, Skoupy S, Fritsch G, Lechner K, Geissler K (1997) Interleukin-10 inhibits spontaneous colony-forming unit-granulocyte-macrophage growth from human peropheral blood mononuclear cells by suppression of endogenous granulocyte-macrophage colony-stimulating factor release. Blood 89:1147–1153
Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH, Glassman AB, Albitar M, Kwari MI, Beran M (2002) Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 99:840–849
Schrader JW (1993) Re-examining the autocrine loop in acute myeloid leukaemia. Adv Cancer Ther 4:5–16
Solal-Celigny P, Desaint B, Herrera A, Chastang C, Amar M, Vroclans M, Brousse N, Mancilla F, Renoux M, Bernard JF, Boivin P (1984) Chronic myelomonocytic leukemia according to FAB classification: analysis of 35 cases. Blood 63:634–638
Wattel E, Guerci A, Hecquet B, Economopoulos T, Copplestone A, Mahe B, Couteaux ME, Resegotti L, Voglova V, Foussard C, Pegourie B, Michaux JL, Deconinck E, Stoppa AM, Mufti G, Oscier D, Fenaux P, Groupe Francais des Myeodysplasies and European CMML Group (1996) A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Blood 88:2480–2487
Worsley A, Oscier DG, Stevens J, Darlow S, Ann Figes, Mufti GJ, Hamblin TJ (1988) Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. Br J Haematol 68:17–21
About this article
Cite this article
Sagaster, V., Öhler, L., Berer, A. et al. High spontaneous colony growth in chronic myelomonocytic leukemia correlates with increased disease activity and is a novel prognostic factor for predicting short survival. Ann Hematol 83, 9–13 (2004). https://doi.org/10.1007/s00277-003-0743-9
- Colony growth
- Chronic myelomonocytic leukemia